PL2291659T3 - Chimeric small molecules for the recruitment of antibodies to cancer cells - Google Patents
Chimeric small molecules for the recruitment of antibodies to cancer cellsInfo
- Publication number
- PL2291659T3 PL2291659T3 PL09746950T PL09746950T PL2291659T3 PL 2291659 T3 PL2291659 T3 PL 2291659T3 PL 09746950 T PL09746950 T PL 09746950T PL 09746950 T PL09746950 T PL 09746950T PL 2291659 T3 PL2291659 T3 PL 2291659T3
- Authority
- PL
- Poland
- Prior art keywords
- recruitment
- antibodies
- cancer cells
- small molecules
- chimeric small
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12753908P | 2008-05-13 | 2008-05-13 | |
EP09746950.6A EP2291659B1 (en) | 2008-05-13 | 2009-05-13 | Chimeric small molecules for the recruitment of antibodies to cancer cells |
PCT/US2009/002957 WO2009139863A2 (en) | 2008-05-13 | 2009-05-13 | Chimeric small molecules for the recruitment of antibodies to cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2291659T3 true PL2291659T3 (en) | 2016-04-29 |
Family
ID=41319210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09746950T PL2291659T3 (en) | 2008-05-13 | 2009-05-13 | Chimeric small molecules for the recruitment of antibodies to cancer cells |
Country Status (14)
Country | Link |
---|---|
US (1) | US8859509B2 (en) |
EP (1) | EP2291659B1 (en) |
JP (1) | JP5746615B2 (en) |
CA (1) | CA2723816C (en) |
CY (1) | CY1118408T1 (en) |
DK (1) | DK2291659T3 (en) |
ES (1) | ES2556629T3 (en) |
HR (1) | HRP20151367T1 (en) |
HU (1) | HUE025618T2 (en) |
PL (1) | PL2291659T3 (en) |
PT (1) | PT2291659E (en) |
RS (1) | RS54428B1 (en) |
SI (1) | SI2291659T1 (en) |
WO (1) | WO2009139863A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2187965T1 (en) | 2007-08-17 | 2020-03-31 | Purdue Research Foundation Office Of Technology Commercialization | Psma binding ligand-linker conjugates and methods for using |
US8852630B2 (en) * | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
JP2012517447A (en) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | Chemically programmed vaccination methods |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
KR20140000275A (en) | 2010-11-18 | 2014-01-02 | 예일 유니버시티 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
US20140308342A1 (en) | 2011-11-11 | 2014-10-16 | Yale University | Reprogramming urokinase into an antibody-recruiting anticancer agent |
ES2905359T3 (en) * | 2012-04-26 | 2022-04-08 | Univ Yale | HIV Targeted Cytotoxic Drug Delivery Molecules (CDM-H), Cytotoxic Activity Against Human Immunodeficiency Virus, and Methods of Use |
WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
EP2919774A4 (en) | 2012-11-15 | 2016-11-09 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP2968596B1 (en) * | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
ES2790420T3 (en) | 2013-03-14 | 2020-10-27 | Scripps Research Inst | Conjugates of antibodies and targeting agents uses of the same |
ES2824026T3 (en) | 2013-05-03 | 2021-05-11 | Univ Yale | Synthetic Antibody Mimetic Compounds (SyAM) Targeting Cancer, Especially Prostate Cancer |
MY194484A (en) | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
CN114262344A (en) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | Charged linkers and their use in conjugation reactions |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
US20230159611A1 (en) * | 2017-07-03 | 2023-05-25 | Yale University | Small molecule adapter regulated, target specific chimeric antigen receptor bearing t cells (smart cars) |
CN113692276A (en) * | 2019-02-19 | 2021-11-23 | 加利福尼亚大学董事会 | NURR1 receptor modulators |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US7033594B2 (en) * | 2000-03-31 | 2006-04-25 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
IL138825A (en) * | 2000-10-03 | 2006-06-11 | Neurim Pharma 1991 | Pharmaceutical formulations containing derivatives of tryptamine and analogous compounds, and some such novel compounds |
US7468354B2 (en) * | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
AU2003205077A1 (en) | 2002-01-10 | 2003-07-30 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
US20080267865A1 (en) * | 2003-11-28 | 2008-10-30 | Biotech Igg Ab | Targeting of Erb Antigens |
AU2005216251B2 (en) * | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
NZ579482A (en) * | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
WO2006015318A2 (en) * | 2004-07-30 | 2006-02-09 | Biogen Idec Inc. | Antibody conjugated to a drug moiety via a poptidic linker |
KR20080031296A (en) | 2005-06-20 | 2008-04-08 | 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 | Psma antibody-drug conjugates |
WO2007011339A1 (en) * | 2005-07-14 | 2007-01-25 | Voyager Pharmaceutical Corporation | Methods for treating and preventing brain cancers |
SI2187965T1 (en) | 2007-08-17 | 2020-03-31 | Purdue Research Foundation Office Of Technology Commercialization | Psma binding ligand-linker conjugates and methods for using |
-
2009
- 2009-05-13 RS RS20150846A patent/RS54428B1/en unknown
- 2009-05-13 JP JP2011509481A patent/JP5746615B2/en active Active
- 2009-05-13 PL PL09746950T patent/PL2291659T3/en unknown
- 2009-05-13 HU HUE09746950A patent/HUE025618T2/en unknown
- 2009-05-13 PT PT97469506T patent/PT2291659E/en unknown
- 2009-05-13 WO PCT/US2009/002957 patent/WO2009139863A2/en active Application Filing
- 2009-05-13 US US12/991,926 patent/US8859509B2/en active Active
- 2009-05-13 ES ES09746950.6T patent/ES2556629T3/en active Active
- 2009-05-13 EP EP09746950.6A patent/EP2291659B1/en active Active
- 2009-05-13 CA CA2723816A patent/CA2723816C/en active Active
- 2009-05-13 SI SI200931337T patent/SI2291659T1/en unknown
- 2009-05-13 DK DK09746950.6T patent/DK2291659T3/en active
-
2015
- 2015-12-10 HR HRP20151367TT patent/HRP20151367T1/en unknown
- 2015-12-15 CY CY20151101148T patent/CY1118408T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2291659A4 (en) | 2011-06-08 |
WO2009139863A2 (en) | 2009-11-19 |
US8859509B2 (en) | 2014-10-14 |
EP2291659A2 (en) | 2011-03-09 |
WO2009139863A3 (en) | 2010-03-04 |
DK2291659T3 (en) | 2015-12-21 |
JP2011523639A (en) | 2011-08-18 |
JP5746615B2 (en) | 2015-07-08 |
US20110201563A1 (en) | 2011-08-18 |
SI2291659T1 (en) | 2016-02-29 |
ES2556629T3 (en) | 2016-01-19 |
EP2291659B1 (en) | 2015-09-16 |
CA2723816A1 (en) | 2009-11-19 |
PT2291659E (en) | 2016-01-22 |
HRP20151367T1 (en) | 2016-01-29 |
CY1118408T1 (en) | 2017-06-28 |
RS54428B1 (en) | 2016-04-28 |
CA2723816C (en) | 2017-06-20 |
HUE025618T2 (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2291659T3 (en) | Chimeric small molecules for the recruitment of antibodies to cancer cells | |
HUS1900006I1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
HK1163134A1 (en) | Antibodies to ccr2 ccr2 | |
IL211176A0 (en) | Methods for the production of ips cells | |
AP4039A (en) | Boron-containing small molecules as antiprotozoal agents | |
EP3375462C0 (en) | Improvements to immobilised biological entities | |
HK1185887A1 (en) | Improved antibody molecules | |
GB0903325D0 (en) | Antibody molecules | |
IL218163A0 (en) | Boron-cotaining small molecules as antiprotozoal agents | |
HK1217711A1 (en) | Antibodies specific to cadherin-17 -17 | |
EP2445513A4 (en) | Chimeric factor vii molecules | |
EP2331134A4 (en) | Anti-pancreatic cancer antibodies | |
ZA201007751B (en) | Novel antibodies used to treat cancer | |
EP2125890A4 (en) | Antibodies to phosphorylated-irak4 | |
EP2212431A4 (en) | Antibodies to irem-1 | |
PT2488554T (en) | Antibodies to epha3 | |
GB201110726D0 (en) | Improvements to immobilised biological entities |